CMS’ Evidence Appraisal Guidance May Clarify CED Mystery To Industry
This article was originally published in The Gray Sheet
Executive Summary
A new CMS guidance document on evidentiary standards could provide more transparency on how the agency arrives at a decision to provide conditional national coverage for a technology while a firm generates additional evidence
You may also be interested in...
CMS Issues Two Of Three Final Guidances On The National Coverage Process
Final guidance clarifying the factors leading CMS to open a national Medicare coverage decision, released April 11, stops short of outlining precise threshold criteria for initiating assessments internally, as had been requested by device manufacturers
Double Duty: Creating Trials To Satisfy Both FDA And CMS
Firms can do "double duty" by gathering economic data during their FDA pivotal trials to get a jump start on CMS coverage, according to Abbott Diagnostic's Barbara Calvert, director of medical products reimbursement
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.